Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALPG | P10696 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | ALPL | P05186 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.32 |
| ▸ | FPR2 | P25090 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19486318 | 0.83 | MAPT (0.33) | MAPTALPGTSHRPLAAALDH1A1 | |
| SCHEMBL28862101 | 0.83 | TLR8 (0.34) | MAPTALPGTSHRPLAAALDH1A1 | |
| SCHEMBL14271655 | 0.83 | ADORA2A (0.37) | MAPTALPGTSHRADORA2AADORA2B | |
| SCHEMBL14254645 | 0.83 | KCNH2 (0.35) | TSHRADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL3025455 | 0.83 | TLR8 (0.34) | MAPTALPGTSHRPLAAALDH1A1 | |
| SCHEMBL5654711 | 0.81 | ADORA3 (0.35) | ADORA3ADORA2AADORA2BADORA1ALDH1A1 | |
| SCHEMBL13439283 | 0.81 | ADORA3 (0.33) | ADORA3ADORA2AADORA2BADORA1FPR2 | |
| SCHEMBL859290 | 0.81 | NR3C1 (0.33) | MAPTADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL1106473 | 0.81 | ADORA2A (0.35) | ADORA3ADORA2AADORA2BADORA1FPR2 | |
| SCHEMBL9444351 | 0.79 | TLR7 (0.39) | ALDH1A1TLR8KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024126777-A1 | HETEROAROMATIC COMPOUNDS | ASTRAZENECA AB (SE) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024129982-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2023228661-A1 | CHEMICAL-RESISTANT PROTECTIVE FILM | 日産化学株式会社 | 2023-11-30 | — | — | WO | disclosed |
| WO-2023228662-A1 | CHEMICAL-RESISTANT PROTECTIVE FILM | 日産化学株式会社 | 2023-11-30 | — | — | WO | disclosed |
| US-11820756-B2 | Bradykinin B2 receptor antagonists | Pharvaris Netherlands B.V. (NL) | 2023-11-21 | — | — | US | disclosed |
| US-20230212629-A1 | COMPOSITIONS AND METHODS FOR PRODUCING CIRCULAR POLYRIBONUCLEOTIDES | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2023-07-06 | — | — | US | disclosed |
| US-20230212629-A1 | COMPOSITIONS AND METHODS FOR PRODUCING CIRCULAR POLYRIBONUCLEOTIDES | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2023-07-06 | — | — | US | disclosed |
| WO-2023056033-A1 | LIPID NANOPARTICLE COMPOSITIONS FOR DELIVERING CIRCULAR POLYNUCLEOTIDES | ORNA THERAPEUTICS, INC. (US) | 2023-04-06 | — | — | WO | disclosed |
| US-20220127271-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC SHP2 INHIBITOR COMPOUND, PREPARATION METHOD, AND USE | SHANGHAI RINGENE BIOPHARMA CO., LTD. (CN) | 2022-04-28 | — | — | US | disclosed |
| EP-3453707-B1 | BENZAZEPINE DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI DE NOVO PHARMATECH CO LTD (CN) | 2022-02-16 | — | — | EP | disclosed |
| US-7342016-B2 | Farnesyl protein transferase inhibitors as antitumor agents | SCHERING CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
| US-7329663-B2 | Substituted-triazolopyrimidines as anticancer agents | WYETH (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329663-B2 | Substituted-triazolopyrimidines as anticancer agents | WYETH (US) | 2008-02-12 | — | — | US | disclosed |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | METHYLGENE, INC. (CA) | 2008-01-03 | — | — | US | disclosed |
| US-7279474-B2 | Substituted pyrrolo[2,3-d]pyrimidines as antagonists of the corticotropin releasing factor (CRF) | GLAXO GROUP LIMITED (GB) | 2007-10-09 | — | — | US | disclosed |
| US-7226950-B2 | Sodium channel modulators | THERAVANCE, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-7226950-B2 | Sodium channel modulators | THERAVANCE, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| WO-2007006418-A1 | IONIC-LIQUID-CONTAINING PRODUCTS FOR DYEING AND/OR BRIGHTENING KERATIN FIBRES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2007-01-18 | — | — | WO | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20050256311-A1 | Pyrimidine compounds | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256311-A1 | Pyrimidine compounds | TYMP, TYMS, CCNT1 | MAPT 4055/4885ALPG 251/4885TSHR 2665/4885 |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | MAPT 2430/4885ALPG 2792/4885TSHR 396/4885 |
| US-20220127271-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC SHP2 INHIBITOR COMPOUND, PREPARATION METHOD, AND USE | PTPN1, PTPN7, PTPN9 | MAPT 4232/4885ALPG 412/4885TSHR 2555/4885 |
| US-11820756-B2 | Bradykinin B2 receptor antagonists | BDKRB2, BDKRB1, VIPR2 | MAPT 3606/4885ALPG 4845/4885TSHR 1138/4885 |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | HGF, ERBB2, MET | MAPT 1806/4885ALPG 2553/4885TSHR 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.